News Release: US House of Representatives
WASHINGTON, D.C. – Today, Congressmen Sanford D. Bishop, Jr. (D-GA) and Peter T. King (R-NY) led 94 of their colleagues in standing strong with hundreds of thousands of men diagnosed with prostate cancer every year by co-writing a bipartisan letter advocating increased funding for prostate cancer research. The funding, if approved, provides $80 million to the Department of Defense Peer-Reviewed Prostate Cancer Research Program (PCRP) for the Fiscal year 2015.
“As a recent cancer survivor myself, I can relate first-hand to the toll that this disease has on millions of Americans each year,” said Congressman Bishop. “The Department of Defense has an outstanding track record in uncovering new and innovative ways to tackle prostate cancer—a leading killer of men—and I am pleased to support this bi-partisan effort to bolster its work and encourage the study, prevention, and treatment of prostate cancer as a national priority on behalf of men in America.”
“My father died from prostate cancer and I have seen firsthand the ravages of this disease. We must make prostate cancer research, awareness and detection a national priority,” said Congressman King “Increased funding for the DoD Peer-Reviewed Prostate Cancer Research Program can do just that. I am proud to work with Rep. Bishop on this critical issue.”
In 2014 alone, it is estimated that more than 230,000 men will be diagnosed with prostate cancer and 29,480 men will die from this disease. According to the American Cancer Society, there were and 800 deaths and 7,600 new cases of prostate cancer in 2014. Federal funding for prostate cancer research has accounted for, on average, only 5% of our nation’s annual cancer research budget even though it is responsible for about 15% of all cancer cases and about 15% of cancer deaths in men. Funding for the PCRP will go towards improving early diagnosis, discovery and development of treatments, develop lab-based discoveries for current patients, and support of advanced research.
To view a copy of the letter, please see attached.